Despite positive clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing significant difficulty from pharmacy benefit managers. The organizations are https://adreayuqc062269.topbloghub.com/48622138/company-s-vyndamax-faces-is-meeting-pbm-challenges-a-look-at-coverage-battles